Hansa Biopharma AB (FRA:24H) Cyclically Adjusted FCF per Share: €-0.81 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:24H Hansa Biopharma AB FRA:24H
60 GF Score
Price €2.79
GF Value €2.03
Valuation Significantly Overvalued
! 5 Warning Signs
View Full Analysis

What is Hansa Biopharma AB Cyclically Adjusted FCF per Share?

Hansa Biopharma AB FRA:24H -4.52% 60 Cyclically Adjusted FCF per Share is €-0.81 as of Jun. 2026. GuruFocus rates FRA:24H with a GF Score™ of 60/100 and a GF Value™ of €2.03 (Significantly Overvalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

Hansa Biopharma AB's adjusted free cash flow per share for the three months ended in Jun. 2026 was €-0.109. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is €-0.81 for the trailing ten years ended in Jun. 2026.

During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -11.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Hansa Biopharma AB was -11.20% per year. The lowest was -17.40% per year. And the median was -14.30% per year.

As of today (2026-07-24), Hansa Biopharma AB's current stock price is €2.79. Hansa Biopharma AB's Cyclically Adjusted FCF per Share for the quarter that ended in Jun. 2026 was €-0.81. Hansa Biopharma AB's Cyclically Adjusted Price-to-FCF of today is .


Hansa Biopharma AB  (FRA:24H) Cyclically Adjusted FCF per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.

For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.


Be Aware

Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.


Hansa Biopharma AB Cyclically Adjusted FCF per Share Related Terms


Hansa Biopharma AB Cyclically Adjusted FCF per Share Historical Data

* Premium members only.

The historical data trend for Hansa Biopharma AB's Cyclically Adjusted FCF per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hansa Biopharma AB Cyclically Adjusted FCF per Share Chart

Hansa Biopharma AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted FCF per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.51 -0.61 -0.74 -0.79 -0.93

Hansa Biopharma AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted FCF per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.88 -0.80 -0.93 -0.80 -0.81

FRA:24H vs VRTX, REGN, ALNY: Cyclically Adjusted FCF per Share Comparison

For the Biotechnology subindustry, Hansa Biopharma AB's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hansa Biopharma AB Cyclically Adjusted Price-to-FCF vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hansa Biopharma AB's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Hansa Biopharma AB's Cyclically Adjusted Price-to-FCF falls into.


FRA:24H
60GF Score
Hansa Biopharma AB FRA:24H
Cyclically Adjusted FCF per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hansa Biopharma AB Cyclically Adjusted FCF per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.

What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?

Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.

We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Hansa Biopharma AB's adjusted Free Cash Flow per Share data for the three months ended in Jun. 2026 was:

Adj_FreeCashFlowPerShare= Free Cash Flow per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=-0.109/134.1100*134.1100
=-0.109

Current CPI (Jun. 2026) = 134.1100.

Hansa Biopharma AB Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201609 -0.090 101.138 -0.119
201612 -0.082 102.022 -0.108
201703 -0.131 102.022 -0.172
201706 -0.114 102.752 -0.149
201709 -0.116 103.279 -0.151
201712 -0.082 103.793 -0.106
201803 -0.115 103.962 -0.148
201806 -0.129 104.875 -0.165
201809 -0.136 105.679 -0.173
201812 -0.145 105.912 -0.184
201903 -0.242 105.886 -0.307
201906 -0.185 106.742 -0.232
201909 -0.190 107.214 -0.238
201912 -0.182 107.766 -0.226
202003 -0.279 106.563 -0.351
202006 -0.185 107.498 -0.231
202009 0.010 107.635 0.012
202012 -0.213 108.296 -0.264
202103 -0.269 108.360 -0.333
202106 -0.254 108.928 -0.313
202109 -0.291 110.338 -0.354
202112 -0.255 112.486 -0.304
202203 -0.279 114.825 -0.326
202206 -0.287 118.384 -0.325
202209 -0.267 122.296 -0.293
202212 -0.217 126.365 -0.230
202303 -0.353 127.042 -0.373
202306 -0.299 129.407 -0.310
202309 -0.310 130.224 -0.319
202312 -0.293 131.912 -0.298
202403 -0.318 132.205 -0.323
202406 -0.266 132.716 -0.269
202409 -0.193 132.304 -0.196
202412 -0.189 132.987 -0.191
202503 -0.204 132.825 -0.206
202506 -0.143 133.699 -0.143
202509 -0.106 133.480 -0.107
202512 -0.160 133.390 -0.161
202603 -0.143 133.560 -0.144
202606 -0.109 134.110 -0.109

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

What does a Cyclically Adjusted FCF per Share of €-0.81 mean?
Hansa Biopharma AB (FRA:24H) has a Cyclically Adjusted FCF per Share of €-0.81 as of Jun. 2026. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Hansa Biopharma AB and its competitors.
Is Hansa Biopharma AB's Cyclically Adjusted FCF per Share too high?
Hansa Biopharma AB's current Cyclically Adjusted FCF per Share is €-0.81. Overall, Hansa Biopharma AB has a GF Score™ of 60/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hansa Biopharma AB's Cyclically Adjusted FCF per Share compare to VRTX and REGN?
Hansa Biopharma AB's Cyclically Adjusted FCF per Share of €-0.81 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted FCF per Share for a Biotechnology company?
A good Cyclically Adjusted FCF per Share depends on the Biotechnology industry context. However, Cyclically Adjusted FCF per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted FCF per Share mean?
A high Cyclically Adjusted FCF per Share can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted FCF per Share represents the company's inflation-adjusted FCF per share over a 10-year period. View historical data on Hansa Biopharma AB and its competitors. Hansa Biopharma AB's current Cyclically Adjusted FCF per Share is €-0.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hansa Biopharma AB stock overvalued right now?
Based on GuruFocus' analysis, Hansa Biopharma AB (FRA:24H) is currently considered Significantly Overvalued. The stock's GF Value™ is €2.03, compared to a current price of €2.79 — trading 37.4% above its estimated fair value. The current Cyclically Adjusted FCF per Share is €-0.81. Hansa Biopharma AB's overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted FCF per Share calculated?
Cyclically Adjusted FCF per Share is calculated from a company's financial statements. For Hansa Biopharma AB (FRA:24H), the current Cyclically Adjusted FCF per Share is €-0.81 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hansa Biopharma AB (FRA:24H) Overvalued in 2026?

Based on GuruFocus' analysis, Hansa Biopharma AB stock appears to be overvalued. The current stock price of €2.79 is trading 37.4% above its estimated GF Value™ of €2.03. GuruFocus considers Hansa Biopharma AB to be Significantly Overvalued.

Key valuation signals for FRA:24H:

  • Cyclically Adjusted FCF per Share: €-0.81
  • GF Value™: €2.03 vs. price of €2.79 (37.4% above fair value)
  • GF Score™: 60/100 with 5 warning signs

No single metric tells the full story. See the FRA:24H stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Hansa Biopharma AB Business Description

Address Scheelevagen 22, Lund, SWE, 223 63
Hansa Biopharma AB is a commercial-stage biopharmaceutical company pioneering the development and commercialization of life-saving and life-altering therapies for patients with rare immunological conditions. It has developed a proprietary, first-in-class antibody-cleaving enzyme technology platform designed to eliminate pathogenic IgG antibodies. This differentiated platform supports a broad pipeline with potential applications across Transplantation, Autoimmune diseases, and Gene Therapy-areas characterized by unmet medical need. Hansa's first-generation IgG-cleaving enzyme, imlifidase, is designed to inactivate all four IgG subclasses (IgG1, IgG2, IgG3, and IgG4) in both the intravascular and extravascular compartments following a single intravenous administration.
60GF Score

Get the complete analysis for FRA:24H

Cyclically Adjusted FCF per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.79
Price
€2.03
GF Value